The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi’s Pemphigus Trial Disappointment, Humanigen’s COVID-19 Drug Denied Emergency Use Authorization
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 8)
See Why Humanigen Stock Is Plunging To 52-Week Low
The FDA declined Humanigen Inc’s (NASDAQ:HGEN) request for emergency use authorization (EUA) of its lenzilumab drug to treat newly hospitalized COVID-19…
Humanigen Shares Fall 52% Premarket After Co Announced FDA Declined Emergency Use Authorization Request for Lenzilumab in Hospitalized COVID-19 Patients
Humanigen, Inc. (Nasdaq: HGEN) announced today the U.S. FDA has declined its request for emergency use authorization of lenzilumab to treat newly hospitalized COVID-19 patients.
Analyzing Humanigen’s Unusual Options Activity
Humanigen (NASDAQ:HGEN) shares experienced unusual options activity on Monday. The stock price moved down to $16.48 following the option alert.
Credit Suisse Maintains Outperform on Humanigen, Lowers Price Target to $24
Credit Suisse analyst Tiago Fauth maintains Humanigen (NASDAQ:HGEN) with a Outperform and lowers the price target from $25 to $24.
Humanigen Q2 EPS $(1.20) Down From $(0.79) YoY
Humanigen (NASDAQ:HGEN) reported quarterly losses of $(1.20) per share. This is a 51.9 percent decrease over losses of $(0.79) per share from the same period last year.
Understanding Humanigen’s Unusual Options Activity
Humanigen (NASDAQ:HGEN) shares experienced unusual options activity on Tuesday. The stock price moved up to $17.53 following the option alert.
Roth Capital Maintains Buy on Humanigen, Lowers Price Target to $32
Roth Capital analyst Tony Butler maintains Humanigen (NASDAQ:HGEN) with a Buy and lowers the price target from $37 to $32.